2 days Ago By ABMN Staff
Commonwealth Equity Services LLC lowered its position in shares of Bausch Health Companies Inc. ( NYSE:BHC – Free Report ) by 25.3% during the fourth quarter, HoldingsChannel reports.
The fund owned 11,905 shares of the company’s stock after selling 4,034 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Bausch Health Companies were worth $96,000 at the end of the most recent reporting period. Other hedge funds and other institutional investors also recently made changes to their positions in the company.
Tobam lifted its holdings in Bausch Health Companies by 10.4% during the 4th quarter. Tobam now owns 15,034 shares of the company’s stock worth $121,000 after buying an additional 1,422 shares during the period.
DGS Capital Management LLC bought a new stake in shares of Bausch Health Companies in the 4th quarter valued at $143,000. Kendall Capital Management increased its position in shares of Bausch Health Companies by 43.4% during the fourth quarter.
Kendall Capital Management now owns 17,995 shares of the company’s stock worth $145,000 after buying an additional 5,445 shares during the period. Principal Securities Inc. increased its position in shares of Bausch Health Companies by 39.
7% during the fourth quarter. Principal Securities Inc. now owns 19,220 shares of the company’s stock worth $155,000 after buying an additional 5,464 shares during the period.
Finally, Aigen Investment Management LP bought a new position in Bausch Health Companies during the fourth quarter worth $180,000. 78.65% of the stock is currently owned by institutional investors.
Bausch Health Companies Stock Performance Shares of NYSE:BHC opened at $4.33 on Friday. Bausch Health Companies Inc.
has a 52-week low of $3.96 and a 52-week high of $9.85.
The business’s 50 day simple moving average is $6.53 and its two-hundred day simple moving average is $7.54.
The firm has a market cap of $1.59 billion, a P/E ratio of -36.04, a PEG ratio of 0.
37 and a beta of 0.43. Analyst Upgrades and Downgrades BHC has been the subject of a number of research analyst reports.
Jefferies Financial Group reiterated a “hold” rating and issued a $8.00 target price (down from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th.
Royal Bank of Canada dropped their target price on shares of Bausch Health Companies from $9.00 to $8.50 and set a “sector perform” rating on the stock in a research report on Monday, April 7th.
One research analyst has rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $7.17.
Get Our Latest Report on Bausch Health Companies Bausch Health Companies Profile ( Free Report ) Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. Featured Stories Want to see what other hedge funds are holding BHC? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Bausch Health Companies Inc. ( NYSE:BHC – Free Report ). Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.
com's FREE daily email newsletter ..
